Some authors have recently described that young patients with invasive macroprolactinomas may present higher prolactin levels when these tumors are resistant to dopamine agonists, which may be associated with genetic causes like multiple endocrine neoplasia (MEN) 1 and pathogenic germline variants in the AIP gene (AIPvar) (25). Here, PRL is linked to multiple endocrine neoplasia type 1.